- Marketwired•2 months agoFirst-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Lixte Biotechnology Holdings, Inc. announced the publication online of Phase 1 results of its novel anti-cancer compound in Clinical Cancer Research, entitled "Safety, tolerability, and preliminary ...
- Marketwired•9 months ago
Lixte Biotechnology Holdings, Inc. announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, ...
- Marketwired•last yearLixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Lixte Biotechnology Holdings, Inc. announced that neuroscientists at the French Institute of Health and Medical Research using a mouse model of depression have identified protein phosphatase 2A as a potential ...
LIXT : Summary for LIXTE BIOTECH HLDGS - Yahoo Finance
Lixte Biotechnology Holdings, Inc. (LIXT)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.10 - 0.10|
|52 Week Range||0.08 - 0.40|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.13|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|